GSK plc (NYSE:GSK) Shares Acquired by Robinson Value Management Ltd.

Robinson Value Management Ltd. boosted its stake in GSK plc (NYSE:GSK) by 2.7% during the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 57,101 shares of the pharmaceutical company’s stock after acquiring an additional 1,494 shares during the period. Robinson Value Management Ltd.’s holdings in GSK were worth $1,931,000 at the end of the most recent reporting period.

Other large investors have also recently added to or reduced their stakes in the company. AQR Capital Management LLC lifted its position in shares of GSK by 103.4% during the second quarter. AQR Capital Management LLC now owns 26,363 shares of the pharmaceutical company’s stock worth $1,015,000 after purchasing an additional 13,403 shares during the last quarter. SG Americas Securities LLC grew its stake in GSK by 167.3% during the 3rd quarter. SG Americas Securities LLC now owns 18,773 shares of the pharmaceutical company’s stock worth $767,000 after buying an additional 11,749 shares during the last quarter. Diversified Trust Co acquired a new stake in GSK in the third quarter worth $308,000. Brookstone Capital Management lifted its stake in GSK by 2.8% in the third quarter. Brookstone Capital Management now owns 26,457 shares of the pharmaceutical company’s stock valued at $1,082,000 after buying an additional 718 shares during the last quarter. Finally, Ritholtz Wealth Management boosted its holdings in shares of GSK by 2.8% during the third quarter. Ritholtz Wealth Management now owns 78,540 shares of the pharmaceutical company’s stock valued at $3,211,000 after acquiring an additional 2,143 shares during the period. 15.74% of the stock is currently owned by institutional investors.

GSK Stock Down 1.0 %

GSK stock opened at $36.03 on Friday. The firm has a market cap of $74.68 billion, a PE ratio of 22.66, a P/E/G ratio of 1.42 and a beta of 0.64. GSK plc has a 12 month low of $31.72 and a 12 month high of $45.92. The company has a debt-to-equity ratio of 1.12, a current ratio of 0.78 and a quick ratio of 0.53. The firm has a 50 day simple moving average of $34.25 and a 200 day simple moving average of $37.57.

GSK (NYSE:GSK) last announced its quarterly earnings data on Wednesday, February 5th. The pharmaceutical company reported $0.59 EPS for the quarter, beating analysts’ consensus estimates of $0.44 by $0.15. GSK had a return on equity of 48.59% and a net margin of 8.13%. Equities research analysts forecast that GSK plc will post 4.07 earnings per share for the current fiscal year.

GSK Increases Dividend

The business also recently declared a quarterly dividend, which will be paid on Thursday, April 10th. Investors of record on Friday, February 21st will be paid a $0.3932 dividend. The ex-dividend date is Friday, February 21st. This represents a $1.57 dividend on an annualized basis and a yield of 4.36%. This is a boost from GSK’s previous quarterly dividend of $0.39. GSK’s dividend payout ratio (DPR) is currently 93.08%.

Analyst Upgrades and Downgrades

A number of research analysts have issued reports on GSK shares. StockNews.com raised shares of GSK from a “buy” rating to a “strong-buy” rating in a research note on Friday. Jefferies Financial Group cut GSK from a “buy” rating to a “hold” rating and decreased their price target for the stock from $53.00 to $39.50 in a research note on Tuesday, November 12th. Deutsche Bank Aktiengesellschaft lowered shares of GSK from a “buy” rating to a “hold” rating in a research report on Friday, November 15th. Finally, Guggenheim lowered shares of GSK from a “buy” rating to a “neutral” rating in a research note on Thursday, October 31st. Six equities research analysts have rated the stock with a hold rating and four have given a strong buy rating to the company. According to data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and an average target price of $43.25.

GSK Profile

GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, and specialty and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through two segments, Commercial Operations and Total R&D.